bioRxiv · 10.1101/2024.09.03.609261
In Silico Target Identification Reveals IL12B as a Candidate for Small Molecule Drug Development
Abstract
Drug discoverys rising costs and complexities require innovative strategies to identify viable therapeutic targets. We developed a computational pipeline to pinpoint protein targets lacking known small molecule probes, focusing on sites traditionally considered challenging for small molecule intervention but validated by FDA-approved biologics. Our approach integrates machine learning, public databases, structural modeling, and functional annotations to prioritize novel binding pockets that overlap biologically validated interfaces. This method identified IL12B as a promising candidate, revealing a previously unexploited surface pocket that overlaps part of the briakinumab epitope. Static protein solvent mapping and dynamic fragment simulations provide convergent evidence of druggability, including fragment-binding clusters and chemically diverse hotspots. While not yet experimentally validated, this site represents a plausible target for orally available IL12B inhibitors. Such compounds could address current clinical limitations of antibody therapies - such as prolonged systemic exposure and infection risk - by enabling a shorter half-life and improved mucosal penetration in diseases like inflammatory bowel disease.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tanner, T. J.. 2024-09-07. In Silico Target Identification Reveals IL12B as a Candidate for Small Molecule Drug Development. https://doi.org/10.1101/2024.09.03.609261
Cite the original work for its findings. Save a collection to share your selection of sources.